A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.
应用场景：
创建时间：
2023-01-15
相关数据集
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started t
NIAID Data Ecosystem60
Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)
Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block t
NIAID Data Ecosystem30
An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.
The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinom
DataCite Commons2025-06-01 更新10
Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery
This phase 0 trial is studying whether 2 weeks of cetuximab and dasatinib will change tumor cells in patients with colorectal cancer and liver metastases that can be removed by surgery. Monoclonal ant
NIAID Data Ecosystem50
Emerging treatment landscape of non-muscle invasive bladder cancer
Non-muscle invasive bladder cancer (NMIBC) accounts for 70–75% of all bladder cancers and is a heterogeneous disease characterized by a wide spectrum of recurrences and progression. Adjuvant treatment
Taylor & Francis Group2023-03-07 更新20
